Literature DB >> 23131889

Drugs associated with restless legs syndrome: a case/noncase study in the French Pharmacovigilance Database.

Santiago Perez-Lloret1, María Verónica Rey, Emmanuelle Bondon-Guitton, Olivier Rascol, And Jean-Louis Montastruc.   

Abstract

BACKGROUND: Several case reports have suggested that drugs could induce restless legs syndrome. However, no systematic review of this adverse drug reaction (ADR) in a pharmacovigilance database has been published.
OBJECTIVE: To assess the frequency of restless legs syndrome in the French Pharmacovigilance Database.
METHODS: We selected all ADR reports from January 1, 1984 to December 31, 2009 coded as restless legs syndrome. Restless legs syndrome diagnosis was validated from case descriptions. Using a case/noncase approach, reporting odds ratio and 95% confidence interval were calculated for "suspected'' drugs with 2 or more observations.
RESULTS: Twenty-six ADR reports were found. Four cases were excluded because of alternative diagnosis. Fourteen cases were women (64%). Median age was 57. Most frequently suspected drugs were antidepressants (reporting odds ratio, 15.9 [6.4-39.7]; amitriptyline, escitalopram, mianserine, mirtazapine, duloxetine), neuroleptics (17.8 [6.1-51.7]; thioridazine, loxapine, risperidone, aripiprazole) or tramadol (18.2 [6.3-52.8]).
CONCLUSIONS: Restless legs syndrome is a very rare ADR that was more frequently reported in association with antidepressants, neuroleptics, or tramadol.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23131889     DOI: 10.1097/JCP.0b013e318272cdd8

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  9 in total

Review 1.  Therapies for Restless Legs in Parkinson's Disease.

Authors:  Valérie Cochen De Cock
Journal:  Curr Treat Options Neurol       Date:  2019-11-09       Impact factor: 3.598

2.  Medications associated with restless legs syndrome: a case-control study in the US Renal Data System (USRDS).

Authors:  Donald L Bliwise; Rebecca H Zhang; Nancy G Kutner
Journal:  Sleep Med       Date:  2014-06-13       Impact factor: 3.492

Review 3.  Gabapentin treatment in clozapine-induced restless legs syndrome: two cases and a review of the literature.

Authors:  Vijaya Kumar; Ganesan Venkatasubramanian
Journal:  Ther Adv Psychopharmacol       Date:  2016-10-12

4.  Asenapine-induced restless legs syndrome: differentiation from akathisia.

Authors:  W Vaughn McCall; Mary Anne Riley; Chelsea Hodges; Laryssa McCloud; Marjorie Phillips; Peter B Rosenquist
Journal:  J Clin Sleep Med       Date:  2014-12-15       Impact factor: 4.062

5.  Clinical features of multifocal papillary thyroid carcinoma and risk factors of cervical metastatic lymph nodes.

Authors:  Yaqiong Ni; Tao Wang; Xingyue Wang; Youxin Tian; Wentao Wei; Qinjiang Liu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-25

Review 6.  Parkinson disease: an update.

Authors:  Steven J Frucht
Journal:  Neurologist       Date:  2004-07       Impact factor: 1.398

Review 7.  Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease.

Authors:  Reyisha Taximaimaiti; Xingguang Luo; Xiao-Ping Wang
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

8.  Impact of disease stage and age at Parkinson's onset on patients' primary concerns: Insights for targeted management.

Authors:  Roongroj Bhidayasiri; Thanatat Boonmongkol; Yuwadee Thongchuam; Saisamorn Phumphid; Nitinan Kantachadvanich; Pattamon Panyakaew; Priya Jagota; Rachaneewan Plengsri; Marisa Chokpatcharavate; Onanong Phokaewvarangkul
Journal:  PLoS One       Date:  2020-12-02       Impact factor: 3.240

9.  Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database.

Authors:  Alexis Revet; François Montastruc; Anne Roussin; Jean-Philippe Raynaud; Maryse Lapeyre-Mestre; Thi Thu Ha Nguyen
Journal:  BMC Psychiatry       Date:  2020-06-16       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.